Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea.

ABSTRACT:

Background

Osteoporosis is a progressive skeletal disease associated with an increased risk of bone fracture. This study aimed to estimate the cost-effectiveness of denosumab for osteoporotic fracture prevention compared to bisphosphonates (alendronate, ibandronate, risedronate, and zoledronate) and selective estrogen receptor modulators (raloxifene) in a cohort of postmenopausal women with osteoporosis.

Methods

A Markov model was used to evaluate the cost and effectiveness of denosumab versus comparators. The model had a cycle length of 6 months and was run from the age of 68 years to individual patients' lifetime or the age of 100 years. The health states considered in the model were well, hip fracture, vertebral fracture, wrist fracture, other osteoporotic fracture, post-

SUBMITTER: Kang JY 

PROVIDER: S-EPMC9208907 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature